Anti-transthyretin humanized antibody
US10604562B2 · kind B2 · utility
0Cited by
1References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 23, 2015 |
| Grant date | Mar 31, 2020 |
| Priority date | — |
| Expiry date | Jan 23, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/7047
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A humanized antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The humanized antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a humanized antibody suitable for application to human body.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.